Argenx Partners With Chai Discovery for AI Antibody...

{
  "signal_id": "f15208f2-70e7-df21-fc7a-3f9d76d58eb5",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-07-16T17:08:52+00:00",
  "company": {
    "name": "Chai Discovery",
    "domain": "chaidiscovery.ai"
  },
  "data": {
    "url": "https://allsci.com/press-release/argenx-taps-chai-discoverys-ai-for-de-novo-antibody-engineering-in-immunology/",
    "title": "Argenx Partners With Chai Discovery for AI Antibody... - AllSci",
    "excerpt": "San Francisco-based Chai Discovery has entered a collaboration agreement with argenx (Euronext & Nasdaq: ARGX) granting the immunology company early access to Chai’s generative AI platform for de novo antibody discovery. The Chai Discovery argenx collaboration is the fourth disclosed pharma partnership for the AI startup in roughly seven months, following agreements with Eli Lilly, Pfizer and Novartis, and marks argenx’s latest move to diversify its discovery toolkit beyond its core FcRn antibody engineering franchise. Financial terms were not disclosed. Under the agreement, argenx scientists gain use of Chai’s platform to design antibody candidates computationally, without a pre-existing template, across unspecified therapeutic targets in immunology. No molecule, target or disease indication has been named, consistent with a discovery-stage tool access arrangement rather than an asset transaction. Chai’s flagship system, Chai-3, is a multimodal generative AI model built on a diffusion-based architecture that predicts and generates three-dimensional molecular structures across proteins, antibodies, nucleic acids and small molecules within a single framework. Its predecessor, Chai-2, released in 2025, was described by the company as the first zero-shot antibody design platform to achieve double-digit experimental hit rates - roughly 16-20% in fully de novo antibody design...",
    "summary": "Chai Discovery has entered into a collaboration agreement with immunology company argenx, granting it early access to Chai's generative AI platform for antibody discovery.",
    "location": "San Francisco, California, USA",
    "planning": true,
    "image_url": "https://allsci.com/wp-content/uploads/2026/07/26f3200b3412944f5c40e07fcc86fbc95909169b103be880941660c40a3ac685_9303459bbe420a16.jpeg",
    "confidence": 0.95,
    "published_at": "2026-07-16T17:08:52Z",
    "location_data": [
      {
        "city": "San Francisco",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "San Francisco-based Chai Discovery has entered a collaboration agreement with argenx (Euronext & Nasdaq: ARGX) granting the immunology company early access to Chai’s generative AI platform for de novo antibody discovery.",
    "related_company_name": "argenx",
    "related_company_domain": "argenx.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f15208f2-70e7-df21-fc7a-3f9d76d58eb5 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"chaidiscovery.ai","limit":20}'